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Abstract
Purpose
To evaluate frequency, conversion rate, and risk factors for blindness in glaucoma patients
treated in European Universities.
Methods
This multicenter retrospective study included 2402 consecutive patients with glaucoma in at
least one eye. Medical charts were inspected and patients were divided into those blind and
the remainder (‘controls’). Blindness was defined as visual acuity0.05 and/or visual field
loss to less than 10°.
Results
Unilateral and bilateral blindness were respectively 11.0% and 1.6% at the beginning, and
15.5% and 3.6% at the end of the observation period (7.5±5.5 years, range:1–25 years); con-
version to blindness (at least unilateral) was 1.1%/year. 134 eyes (97 patients) developed
blindness by POAG during the study. At the first access to study centre, they had mean devia-
tion (MD) of -17.1±8.3 dB and treated intraocular pressure (IOP) of 17.1±6.6 mmHg. During
follow-up the IOP decreased by 14% in these eyes but MD deteriorated by 1.1±3.5 dB/year,
which was 5-fold higher than controls (0.2±1.6 dB/year). In a multivariate model, the best pre-
dictors for blindness by glaucoma were initial MD (p<0.001), initial IOP (p<0.001), older age at
the beginning of follow-up (p<0.001), whereas final IOP was found to be protective (p<0.05).
Conclusions
In this series of patients, blindness occurred in about 20%. Blindness by glaucoma had 2
characteristics: late diagnosis and/or late referral, and progression of the disease despite in
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most cases IOP was within the range of normality and target IOP was achieved; it could be
predicted by high initial MD, high initial IOP, and old age.
Introduction
The socio-economic impact of glaucoma is very high mainly due to its epidemiology and the
effects on visual function. The disease has a high prevalence (> 66 million people worldwide)
and is the second leading cause of irreversible blindness (>7 million people bilaterally blind
worldwide) [1]. A recent review found that glaucoma is responsible for 10–11% of blindness in
Western Europe and U.S., and this percentage is increasing in the last decade [2]. Progressive
glaucomatous visual field (VF) impairment is associated with reduced vision-related quality of
life [3,4] and higher social costs [5].
The visual outcome is the major concern of glaucoma patients [6]. At diagnosis, 34% are
worried about the probability of becoming blind in the future; even if this percentage decreases
to 11% at follow-up, fear is still very high for patients with severe field deterioration and pro-
gression [7].
The topic of blindness in glaucoma is still controversial despite its relevance. Prospective
studies provided estimates for blindness due to primary open-angle glaucoma (POAG) in at
least one eye of 15–27%, and in both eyes of 6–12%, with incidence of about 1% per year (fol-
low-up ranging from 15 to 34 years) [8–11], but other studies suggested that blindness inci-
dence is declining due to the advent of modern treatments [12,13]. A recent study fromMalmo
(Sweden) on a cohort of about 600 patients followed from diagnosis to death found a preva-
lence of 42% of blindness in one eye and 16% in both eyes at the last visit [14]. A Chinese study
on primary angle-closure glaucoma (PACG) estimated blindness at presentation as 6% and
30.1% based on visual acuity (VA) and visual field (VF) criteria with a progression to blindness
in 7% over a 10-year follow-up [15]. Large differences can be due to race [16] and, moreover,
the several definitions of blindness may raise confusion [17,18]. Most of these studies were con-
ducted on small samples of selected patients with exclusion of ocular comorbidities, so that a
clear scenario of the prevalence and causes of blindness in glaucoma practice is still only par-
tially depicted.
The aim of this study is to report on the frequency, conversion, causes and risk factors of
blindness in a large cohort of glaucoma patients from different academic centers.
Materials and Methods
This retrospective data review involved 7 European sites: the University Eye Clinics of Milan
(San Paolo Hospital), Turin, Genoa, Pisa, Siena, Rome (Tor Vergata)–Italy, and the Depart-
ment of Ophthalmology, Miguel Servet Hospital, University of Zaragoza, Zaragoza–Spain. The
study was approved by the Ethics Committee at each study site, and respected the tenets of the
Declaration of Helsinki and national laws for the protection of personal data. Written informed
consent was obtained from all the participants.
Each of the seven centres included 350 patients with a documented diagnosis of POAG in at
least one eye; excluded were patients with age<18 years and cases of ocular hypertension or
glaucoma suspect. Patients’ data were retrieved between January and June 2010 from the Hos-
pital databases in alphabetical order; in case of families, only the first patient in the database
was included. No selection was done based on patients provenance (included were both
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referred and non-referred patients, at any stage of severity of the disease), VF, optic nerve head,
intraocular pressure (IOP) or VA.
A diagnosis of glaucoma was accepted if at least one eye had a repeatable VF change consis-
tent with glaucoma together with a glaucomatous optic nerve head appearance (manifest glau-
coma). Patients with POAG had to have an open-angle and no secondary cause of IOP
elevation. For the purposes of the study, blindness had to be attributed to a single pathology
between POAG, PACG, macular degeneration, high myopia, vein occlusion, trauma, retinal
detachment, diabetes, and corneal pathologies. The cause of blindness was determined by
reviewing the patient charts and through analysis of the VFs; in presence of comorbidity, con-
sensus between investigators was reached.
The World Health Organisation (WHO) definition of blindness was used [14,19]: best-cor-
rected VA of less than 0.05 and/or VF loss to less than 10°. Blindness criteria were confirmed
by at least two consecutive visits. Patients with reversible blindness (due to perimetric variabil-
ity, cataract surgery, or glaucoma course itself; see Results section) were not analyzed as blind.
Perimetries were performed at all sites using Humphrey Field Analyzer 750 (Carl Zeiss Medi-
tec, Dublin, CA, USA), full-threshold or SITA Standard programs over the central 30 or 24
degrees, using III spot size.
For each included patient we recorded age, sex, medical history (cardiovascular factors
included diabetes, carotid stenosis cardiac and vascular diseases except Horton disease), any
eye surgical procedures, number of visits, procedures performed at each visit, an anterior and
posterior segment description, VF, VA, IOP values, type of ocular treatment, adherence to
treatment and referral to study center, as derived from medical charts. Time-points were: date
of diagnosis (when a glaucomatous VF defect together with an optic nerve head damage was
first shown), date of the first visit at the study center (beginning of follow-up), date of occur-
rence of blindness (if this was the case), date of the last visit (end of follow-up).
Statistical analysis
The whole sample was analyzed to assess the global frequency (or prevalence), conversion rate
(or incidence) and the different causes of blindness. The risk of conversion to blindness was
evaluated only among patients diagnosed with POAG. To account for different follow up times
and time varying covariates, a parametric accelerated failure model (Weibull distribution) was
used. Model included stratification by center to account for between-center variability. For
each patient, blindness from glaucoma of at least one eye occurring during the time of observa-
tion was considered as an event (failure). Since the exact time of occurrence of blindness was
not available, interval censoring was used. For covariates that implied one observation from
each eye (i.e. Mean Deviation, MD, and IOP), the mean of the two values was calculated for
each patient. Finally, a standard linear model was used to investigate the final MD and its cor-
relation with different covariates. In this case, each eye was considered individually and corre-
lation between observations was corrected with the addition of random effects (for both
subject and center factors). Different number of cases and observations among fitted models
are due to missing values for the different covariates considered in each case. Models were
modified to avoid obvious multicollinearity among predictors (e.g. the final IOP and the initial
IOP were never in the same model, see Results). All calculations were performed in R scripting
environment [20–23].
Results
A total of 2,402 patients were included in the dataset; race was Caucasian in 99%, other in 1%
(African n = 18, Hispanic n = 6, Indian n = 3); 99% of patients were literate; 55% were female.
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In 52 cases, blindness at the first visit was not confirmed at follow-up: 27 eyes had VA improve-
ment thanks to cataract surgery; 6 had sudden IOP reduction (of these 6 referred patients, 4
received trabeculectomy, and 2 trabeculoplasty and maximum-tolerated medical treatment)
and were not confirmed as blind due to VF; finally, 19 patients showed perimetric learning
effect. All of these subjects were included in the analysis as non-blind patients.
Mean age of the study population at the beginning of follow-up was 68.7±11.5 years, with
a statistically significant difference between non-blind (66.8±11.8 years) and blind patients
(72.0±10.1 years, P<0.0001). Mean follow-up was 7.5±5.5 years (median 7, range 1–25 years);
for non-blind patients it was 7.3±5.4 years (median 7, range 1–24 years), for blind patients 8.4
±6.0 years (median 8, range 1–25 years, P = 0.047). Blindness occurred at 73.3±10.2 years; 70%
of the totality of blind cases occurred before referral to the study centers; 51% of blind patients
were female.
At the beginning of follow-up, the frequency of unilateral blindness was 11.0% (262 eyes;
262 patients), whereas bilateral blindness was present in 1.6% (39 patients). At the end of the
study, the frequency of unilateral and bilateral blindness respectively increased to 15.5% (372
eyes of 372 patients) and 3.6% (86 patients).
The number of eyes converted to blindness in the course of the study was 204 of 157
patients. In these patients, the mean time elapsed from first observation to blindness was
4.6 plusmn;3.0 years (range: 1–21 years). Conversion to blindness (at least unilateral) was
1.1% per year. Frequency of blindness was similar between centres (p>0.20, Weibull test).
The causes of blindness are reported in Table 1. As expected, POAG was the main cause
(61.4%), whereas PACG accounted for 7.2% of cases. Glaucoma patients frequently had other
eye diseases determining blindness: macular degeneration (7.6%), high myopia (5.7%), vein
occlusion (4.8%), trauma (3.5%), retinal detachment (3.1%), diabetes (1.5%), and corneal
pathologies (1.3%). When the analysis was restricted only to eyes that converted to blindness
during the study, similar figures were found with the exception of a lower prevalence of trauma,
retinal detachment and corneal pathologies.
Further analysis was conducted on eyes blind due to POAG (n = 334). 60% (n = 200) were
blind at first observation, whereas 40% (n = 134) developed blindness due to POAG during the
study period. For the 200 eyes of patients blind by POAG at the beginning of the study, the
Table 1. Causes of blindness in the study.
Causes % of blind eyes at the end of
the study (n = 544)
% of eyes converted to blindness
during the study (n = 204)
POAG 61.4 65.6
PACG 7.2 5.7
ARMD 7.6 7.6
Myopia 5.7 7.6
Vascular diseases
(BVO, CVO)
4.8 7.6
Trauma 3.5 1.3
Retinal detachment 3.1 1.3
Diabetic retinopathy 1.5 1.9
Cornea 1.3 0.6
Other 3.9 0.6
ARMD, age-related macular disease; BVO, branch vein occlusion; CVO, central vein occlusion; PACG,
primary angle-closure glaucoma; POAG, primary open-angle glaucoma.
doi:10.1371/journal.pone.0136632.t001
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criterion of blindness was VF in 93%, VA in 12%, and both in 5%. These patients were referred
to the study centers more frequently than non-blind cases (53% vs 40%, P<0.001) and had MD
of -26.5±4.8 dB at first examination.
The 134 eyes who developed blindness by POAG in the course of the study had MD of
-17.1±8.3 dB (median -17 dB) and IOP of 17.1±6.6 mm Hg (median 17 mmHg) at presenta-
tion (Table 2). The main feature of these patients is that their fields deteriorated regardless of
aggressive IOP treatment: all patients received maximum-tolerated medical treatment and,
in 75% of cases, glaucoma laser or surgery; this determined a further mean IOP decrease to
14.6±3.5 mm Hg (median 14 mmHg, -14%).
In these 134 eyes, the rate of MD change was -1.1±3.5 dB / year, which was 5-fold higher
than non-blind subjects (-0.2±1.6 dB / year). As expected, some comorbidities were associated
with increased rate of progression: the rate of change was -1.8±1.1 dB / year in presence of
macular degeneration, and -3.1±1.4 dB / year in presence of vein occlusion. Myopia did not sig-
nificantly modify the rate of perimetric progression, apart in 3 eyes having a mean change of
-1.9 dB / year.
Next, analysis of conversion rate was performed on patients who had at least one eye at risk
at the beginning of the study (i.e. not blind) and whose conversion could not be attributed to
different causes other than POAG and for whom complete data were available. In this analysis
1606 patients were analyzed and 53 converted to blindness from at least one eye by the end of
follow up. Of the covariates analyzed in the survival model for blindness, only age at the begin-
ning of the follow up, initial MD value and final IOP have shown to be significant predictors.
Table 3 shows the same multivariate survival model fitted with the Initial IOP or the Final IOP
Table 2. Characteristics of IOP in patients developing blindness by POAG in the course of the study.
Beginning of the study End of the study
Mean IOP (mmHg) 17.1 ± 6.6 14.6 ± 3.5
Range (mmHg) 8–56 6–36
IOP > 18 mm Hg (%) 17% 9%
IOP, intraocular pressure (mean of the two eyes).
doi:10.1371/journal.pone.0136632.t002
Table 3. Multivariate survival model fitted with the Initial IOP (first column) or the Final IOP (second
column) as predictors, together with mean Initial MD and Age.
Blindness, Weibull parameter estimates (standard error)
Age -0.029 (0.013)** -0.027 (0.013)**
Mean MD 0.105 (0.023)*** 0.110 (0.024)***
Mean Final IOP 0.090 (0.036)** -
Mean Initial IOP - 0.016 (0.028)
Intercept 6.987 (1.212)*** 7.996 (1.357)***
Observations 1,606 1,606
*p<0.1
**p<0.05
***p<0.01
IOP, intraocular pressure; MD, Mean Deviation; Initial, at the beginning of follow up; Final, at the end of
follow up.
Since all calculations were made to estimate the probability of becoming blind from at least one eye, MD
and IOP value were calculated for each subject as the mean of the values from the affected eyes.
doi:10.1371/journal.pone.0136632.t003
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as predictors, together with mean Initial MD and Age. Since all calculations were made to esti-
mate the probability of becoming blind from at least one eye, MD and IOP value were calcu-
lated for each subject as the mean of the values from the affected eyes. As expected, the major
risk factor was the severe initial MD (p<0.0001), which can be thought as an indicator of the
stage of the disease at the beginning of the follow up. Higher age at the beginning of the study
was a significant risk factor for blindness (p<0.0001). Final IOP interestingly showed a slightly
protective effect (p = 0.008) meaning that eyes with lower pressure values at the end of the
study were more likely to become blind.
Table 4 shows the hazard ratios for each risk factor. Since the model used is a parametric
accelerated failure model with a Weibull distribution, the hazard ratio depends on the scale
parameter, which is different for each center due to stratification. The presented hazard ratios
are a global calculation (i.e. with no strata) although the significance of the covariates was
assessed with a stratified model. Similar results could be found by analyzing the correlation
between the same variables and the MD at the end of the follow up.
Tables 5 and 6 show the same multivariate linear model fitted with Final MD values as
dependent variable and Initial IOP (Table 5) or Final IOP (Table 6) as predictors, together with
other predictors. Table 7 shows a multivariate regression of the Initial MD value on the other
predictors in Table 5. Again, the initial MD value was the best predictor of the final MD
Table 4. Hazard ratios and confidence intervals for each risk factor in determining blindness.
HR Lower 95% CI Upper 95% CI
Age 1.0321506 1.0082546 1.0566128
Mean MD 0.8962068 0.8690180 0.9242462
Mean Final IOP 0.9040504 0.8394736 0.9735948
IOP, intraocular pressure; MD, Mean Deviation; Final, at the end of follow up. Since the model used is a parametric accelerated failure model with a
Weibull distribution, the hazard ratio depends on the scale parameter, which is different for each center due to stratification. The presented hazard ratios
are a global calculation (i.e. with no strata) although the significance of the covariates was assessed with a stratified model.
doi:10.1371/journal.pone.0136632.t004
Table 5. Table shows a multivariate linear model fitted with Final MD values as dependent variable
and Initial IOP as predictor, together with other predictors.
Final MD, Estimated parameters (standard errors)
Cardiovascular -0.238 (0.229)
Hypertension 0.104 (0.185)
Hypotension -0.318 (0.500)
Non Family History of Glaucoma -0.311 (0.194)
Initial MD 0.841 (0.012)***
Age -0.043 (0.007)***
Follow up time -0.138 (0.025)***
Initial IOP -0.061 (0.016)***
Intercept 3.492 (0.589)**
Observations 3,246
Log Likelihood -9,076.319
*p<0.1
**p<0.05
***p<0.01
IOP, intraocular pressure; MD, mean deviation
doi:10.1371/journal.pone.0136632.t005
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(p<0.0001, correlation coefficient 0.9). Besides the obvious correlation with the follow up time,
other important factors were age (p<0.0001) at the beginning of the follow up and surprisingly
the initial IOP (p<0.0001) but not the final IOP. This latter apparent discrepancy shows that
the final IOP had indeed little role in the actual progression of the visual field impairment,
besides the efforts taken to lower the pressure levels in these patients. On the other hand, the
significant correlation with the initial IOP can be better explained considering its role in deter-
mining the initial MD value (Table 7).
Initial MD was also strongly correlated with the presence of cardiovascular factors (which
included diabetes, carotid stenosis and cardiac diseases). However, multicollinearity of predic-
tors (as evident from Table 7) can limit the validity and consequently the interpretation of
these models.
Table 6. Multivariate linear model fitted with Final MD values as dependent variable and Final IOP as
predictor, together with the same predictors as in Table 5. (except for the Initial IOP).
Final MD, Estimated parameters (standard errors)
Cardiovascular -0.236 (0.230)
Hypertension 0.115 (0.185)
Hypotension -0.290 (0.501)
Non Family History of Glaucoma -0.289 (0.195)
Initial MD 0.843 (0.012) ***
Age -0.041 (0.007) ***
Follow up time -0.140 (0.025) ***
Final IOP -0.009 (0.024)
Intercept 2.401 (0.638) **
Observations 3,246
Log Likelihood -9,082.704
*p<0.1
**p<0.05
***p<0.01
IOP, intraocular pressure; MD, mean deviation
doi:10.1371/journal.pone.0136632.t006
Table 7. Multivariate regression of the initial Mean Deviation on the other predictors of Table 5.
Initial Mean Deviation, Estimated parameters (standard errors)
Cardiovascular -0.991 (0.374) ***
Hypertension 0.315 (0.303)
Hypotension -1.200 (0.821)
Non Family History of Glaucoma -0.377 (0.318)
Age -0.100 (0.011)***
Initial Intraocular Pressure -0.065 (0.026)**
Intercept 2.306 (0.922) **
Observations 3,246
Log Likelihood -10,386.370
*p<0.1
**p<0.05
***p<0.01
doi:10.1371/journal.pone.0136632.t007
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Discussion
This paper explored the epidemiology and causes of blindness in a group of patients followed
by the “Glaucoma Services” of 7 academic centers. Unilateral and bilateral blindness was
respectively 11.0% and 1.6% at the beginning of the study, and 15.5% and 3.6% at the end of
the observation period (7.5±5.5 years), with a conversion of 11 new blind patients/1,000 per
year.
Overall, these findings are consistent with those from prospective studies [8–11]. In our
dataset, causes of blindness other than POAG and PACG accounted for about 30% of cases
(Table 1). The WHO criteria used in this study are by far more restrictive than those for legal
blindness (VA< 0.1 and/or VF constriction within central 20°) used in other studies [8–13].
WHO criteria, to us, address the concept of “blindness” better than legal criteria: most of our
patients with VF constriction at 20° can lead a normal life, apart from driving restriction, and
in the US it is estimated that 90% of “legally blind” subjects have residual vision [16].
As confirmed by previous studies [10,17], blind patients were older than controls; no signifi-
cant sex difference was found. In glaucoma patients developing blindness during the study,
blindness was associated with late detection of the disease [24,25], advanced VF damage at
diagnosis [11,26–28]; these patients were referred to the study centers more frequently than
controls [24].
IOP is considered a major risk factor for progression to blindness in glaucoma [11,28–32].
In our study patients going blind progressed despite IOPs in the ‘normal’ range (17.1±6.6 mm
Hg–values very close to Chen’s study [8]). In this group, some patients had very high IOP val-
ues (maximum IOP was 56 mmHg), so that, if these outliers had been excluded, mean IOP
would have been even lower. During the study, further IOP reduction of 14% was obtained, but
this did not halt VF progression, in contrast with the data of the Canadian Glaucoma Study
[33]. Possible explanations include the different amount of IOP reduction in the 2 studies and
the fact that, differently from our study, in the Canadian Glaucoma Study a target IOP was
searched in all progressing patients. On the other side, we confirmed the role of sudden IOP
reduction in recovering visual function, at least on a minority of patients [34–36].
These results clearly show that one of the major determinants of blindness and disease pro-
gression in glaucoma is the initial condition of the patients upon referral to second level cen-
ters. Although this might seem obvious, it points out that correct timing in diagnosis and
treatment is fundamental to properly control visual field loss and prevent blindness. It is
important to notice that in this study, known important factors, such as IOP and cardiovascu-
lar factors, were only significant in determining the initial MD value. This could either depend
on the fact that the follow up period was not sufficient to properly evaluate the effect of such
variables or to the fact that proper timing and treatment can effectively control the progression
of the disease in spite of these differences among patients. Of course, this analysis suffers from
the fact that only few patients (slightly more that 2% of the considered eyes) were blind at the
end of the study. Nevertheless, these conclusions are also supported by the analysis on the pro-
gression of visual field loss which eliminates any distortion introduced by the “threshold” effect
intrinsic to the definition of blindness.
The initial IOP could be considered as an indicator of pressure control before entering the
study and thus important in setting the initial visual field condition and, secondly, the final
MD.
Higher final IOP was found to be protective for blindness. This paradox could be explained
considering that patients at risk of becoming blind in a short time (typically patients with
advanced glaucoma) usually receive aggressive IOP-lowering treatments, although this is fre-
quently insufficient to prevent blindness. It is therefore evident that final IOP may have a small
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role in the actual progression of VF damage, despite the efforts taken to lower the pressure lev-
els in these patients.
We explored the effect of age at the beginning of follow up and our results matched the find-
ings of other reports [14,37], showing that older patients are more susceptible to visual
impairment and blindness by glaucoma. It is unlikely that these differences could arise from
different disease durations since the initial MD values considered in the multivariate analysis
served also as a control factor for the initial patient conditions.
Cardiovascular factors were found to be significantly correlated with more negative initial
MD values but not with final MD values and the risk of blindness. This could be explained by
the fact that cardiovascular factors are more important on long time periods, thus setting the
initial severity of visual field impairment, but are not crucial on a smaller time scale, i.e. the
duration of follow up. Caution is necessary when evaluating these data, as cardiovascular fac-
tors (as well as hypertension and hypotension anamnestic data) were self reported by patients
regardless of chronic treatments and control of the diseases.
Our study has some strengths and limitations. The strengths include the large dataset, the
absence of any patient selection, and the data consistency between centers. Moreover, we used
the stringent criteria for blindness suggested by WHO and we confirmed blindness frequencies
given by Forsman [9] and Oliver [11]. On the other hand, our results may be limited by the ret-
rospective design of the study and the fact that the quality of the analysis relies on the quality of
the medical charts. This is particularly relevant for the study of risk factors, which was based
exclusively on the medical history referred by patients. Also, we preferred not to divide POAG
from pseudoexfoliative, pigmentary, and normotensive glaucoma, even if these glaucomas
have different prognosis [38]. In fact, a precise diagnosis could not be done in many cases
(absence of or inadequate baseline data in referred patients; cataract surgery, which could alter
a correct assessment of pseudoexfoliation and pigmentary glaucoma). In such a study, it is also
hard to separate the effects of cataract on the progression of VF mean deviation.
The principal limitation of this study is that patient catchment of the academic centres is
unlikely to represent the patient catchment of the hospital system as a whole. In fact, study cen-
tres have their own catchment from the community (i.e. patients requiring an ophthalmic
examination have unrestricted access to a primary eye care service), but also a significant num-
ber of tertiary referrals (i.e. patients seen in other hospitals for various reasons, including the
need for assistance with management of severe glaucoma). It should be noted that the preva-
lence of blindness by glaucoma in our study is similar to literature [8–11]; we therefore assume
that the effect of a selection bias, if present, is not large. Yet, in our study, 70% of all blind cases
occurred before referral to the study centres. Strategies of data capture across hospital systems
as a whole are recommendable in order to depict a clear scenario of the burden of blindness
associated with glaucoma in hospital care; the progressive use of digitized data and telemedi-
cine will be helpful in this process.
To summarize, this paper has the merit of showing that glaucoma is still a very dangerous
disease, as about 20% of glaucoma patients followed in University Eye Clinics are blind in at
least one eye. Glaucomas caused 70% of blindness, and two features could be identified for
these patients: late diagnosis and/or late referral, and progression of the disease despite “gener-
ally accepted” IOP values. Patients going blind had a decrease of mean deviation of about 1 dB/
year, which is very similar to the natural history of untreated Caucasian glaucoma patients
[39], and five-fold higher than non-blind glaucoma patients.
Screening strategies for glaucoma have been shown to be inadequate in view of the ratio
between costs and effectiveness. Still, the problems of late diagnosis and of the high frequency
of blindness remarked by this paper highlight the inadequacy of the current strategies for glau-
coma diagnosis, even in 2012 in so-called “developed” Countries.
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Finally, we showed that people going blind progress more rapidly than controls and that, in
advanced stages, progression seems to become less affected by IOP reduction. We therefore
recommend to assess risk factors, to measure VF progression and to provide aggressive treat-
ments in patients showing high progression (loss of mean deviation>1dB/year) at earlier
stages, in order to reduce the likelihood of developing blindness.
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